Reporting in Nature, Kumar and colleagues have now developed a method to target small-interfering RNA (siRNA) to the CNS, providing a safe and non-invasive approach for the delivery of this new ...

Marlborough, Massachusetts--(Newsfile Corp. - April 3, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biotechnology company developing therapeutics using its ...

SIL204 is a next-generation siRNA candidate targeting KRAS-driven cancers. In preclinical trials, a single administration of SIL-204 encapsulated in an extended-release formulation yielded tumor ...